Conatumumab (originally AMG-655) is a monoclonal antibody developed for the treatment of cancer. It is a fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2, death receptor 5) with potential antineoplastic activity.[1][2] Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin.[3][4]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | TRAIL-R2 (CD262) |
| Clinical data | |
| Other names | anti-TRAIL receptor 2 monoclonal antibody, AMG-655 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6466H10006N1730O2024S40 |
| Molar mass | 145645.66 g·mol−1 |
  (what is this?) (verify) | |
The drug was developed by Amgen Inc. In 2008, Takeda licensed the drug from Amgen for development in Japan, but discontinued development in 2011.
References edit
- ^ Rosevear HM, Lightfoot AJ, Griffith TS (June 2010). "Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancer". Current Opinion in Investigational Drugs. 11 (6). London, England: 688–98. PMID 20496264.
- ^ Bajaj M, Heath EI (November 2011). "Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults". Expert Opinion on Biological Therapy. 11 (11): 1519–24. doi:10.1517/14712598.2011.610788. PMID 21877997. S2CID 28520935.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council – Conatumumab, American Medical Association.
- ^ National Cancer Institute: Definition of conatumomab
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |